Life Science Investing BioAtla to Present Clinical Data for Mecbotamab Vedotin in Soft Tissue Sarcoma at SITC 2025
Life Science Investing BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma Following Productive Type B Meeting with FDA
Standard Uranium Announces Expansion of Davidson River Drill Program and Provides Update on Private Placement and LIFE Offering